The Company’s presentation is scheduled to begin at 10:30 AM EDT.

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap

About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm’s presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.

The Company will present the mechanism data of RX-5902 in a poster (abstract #5507) entitled, “Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902),” on Wednesday, April 10, 2013, during the “Chemotherapy and Cancer Dependencies” poster session from 8:00 am – 12:00 pm EDT in Exhibit Hall A-C, Poster Section 37.

For more information on the AACR conference, please visit www.aacr.org.

About RX-5902
RX-5902 is an orally bioavailable, first-in-class inhibitor of p68 RNA helicase for the treatment of various solid tumors, such as melanoma and cancers of the ovary, kidney and pancreas. Rexahn has filed an IND for RX-5902 and anticipates initiating Phase I clinical development in the second quarter of 2013.

RX-5902 has been shown to produce potent anti-tumor effects, increased survival in xenograft models, anti-proliferative activity in drug-resistance cancer cell lines and synergistic effects with known anti-cancer drugs.

RX-5902 is part of a growing pipeline of clinical stage oncology compounds that Rexahn is developing to potentially provide improved efficacy and reduced toxicity, resulting in improved survival and quality of life for patients.

About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

Safe Harbor
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Rexahn’s plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn’s licensees or sublicensees; the success of clinical testing; and Rexahn’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect Rexahn’s actual results are described in Rexahn’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing and commercializing first in class therapeutics for the treatment of cancer and other unmet medical needs. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

####

[URL]

What has driven me throughout my 25 years in the pharmaceutical industry is the desire to do something that would translate into new therapies to help patients.

When I look back on my career now, I’m fortunate to say that I’ve been able to do that, …..

Click here for more information

Position: Chief executive of Rexahn Pharmaceuticals, a clinical-stage biotechnology company in Rockville.

With a father who ran three businesses in New York City, Peter Suzdak knew as a child that he would wind up in business. After obtaining a doctorate and serving a fellowship at the National Institutes of Health, he became fascinated with the process of taking …..